Tokyo, Dec. 6 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059987) titled 'A Prospective Observational Study on the Dynamics of Claudin18.2, PD-L1, and HER2 Expression Following First-Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.' on Dec. 5.
Study Type:
Observational
Primary Sponsor:
Institute - St. Marianna University School of Medicine
Condition:
Condition - To investigate the potential usefulness of zolbetuximab, primarily as a second-line or later treatment, by evaluating changes in key biomarkers, including Claudin 18.2 (CLDN18.2), before and after first-line treatment for unresectable gastric cancer and gastroesophageal junction cancer...